Ver el código de «Sedative/hypnotic withdrawal»

==Background==
Sedative/hypnotics, including benzodiazepines, barbiturates, and non-benzodiazepine "Z-drugs" (e.g., zolpidem, eszopiclone), are commonly prescribed for anxiety, insomnia, and seizure disorders. While effective in the short term, these agents carry a significant risk for tolerance, physical dependence, and withdrawal upon abrupt discontinuation. The underlying pathophysiology of withdrawal stems from chronic modulation of gamma-aminobutyric acid (GABA) receptors, resulting in a state of central nervous system hyperexcitability when the inhibitory effect is suddenly removed <ref> Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990. </ref>. Sedative/hypnotic withdrawal remains underrecognized in clinical practice despite its potentially life-threatening complications, such as seizures and delirium <ref> Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003. </ref>.

==Clinical Features==
For short-acting agents like alprazolam or zolpidem, withdrawal can begin within 6–24 hours after the last dose. Long-acting agents like diazepam may produce symptoms after several days.

Common features include:

Mild: anxiety, insomnia, restlessness, tremors, diaphoresis

Moderate: palpitations, nausea, myoclonus, perceptual disturbances

Severe: hallucinations, psychosis, seizures, and delirium tremens-like presentations

Symptoms typically peak within 48–72 hours but can persist for weeks, especially with long-term use. <ref> Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry. 1990. </ref> A clinical feature distinguishing sedative/hypnotic withdrawal from alcohol withdrawal is the potential for prolonged symptoms due to the long half-life of some agents.

==Differential Diagnosis==
{{Sedative/hypnotic withdrawal types}}

==Evaluation==
A detailed history is critical and should include dose, duration, and timing of last sedative/hypnotic use. Collateral information, such as pharmacy records or reports from family members, may be necessary.

Recommended evaluation includes:

Vital signs and mental status examination

Basic labs: CBC, CMP, magnesium, phosphate

Urine toxicology screen (although many sedative agents may not be detected)

ECG, especially in older adults or those with suspected overdose

Consider brain imaging if focal deficits or atypical presentation

Clinical assessment tools such as the [[Clinical Institute Withdrawal Assessment for Benzodiazepines]] (CIWA-B) may be used, although less widely validated than CIWA-Ar for alcohol withdrawal. <ref> American Psychiatric Association. Practice Guideline for the Treatment of Patients with Substance Use Disorders. 2nd ed. 2006. </ref>

==Management==
Benzodiazepines are the treatment of choice, especially diazepam or lorazepam due to favorable pharmacokinetics <ref> Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003. </ref>.

Titrate to symptom control using a symptom-triggered or fixed-dosing protocol.

Phenobarbital is a second-line option, particularly in refractory cases or for tapering high-dose benzodiazepine users <ref> Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003. </ref>.

Supportive care: fluids, nutrition, quiet environment, seizure precautions

In severe cases with seizures or delirium, ICU monitoring is warranted.

Referral to long term care is necessary

==Disposition==

Patients presenting with severe withdrawal symptoms—such as seizures, delirium, or hemodynamic instability—require inpatient admission, often to a monitored setting. Patients with mild to moderate symptoms who are medically stable, have reliable follow-up, and are motivated may be managed as outpatients with a clear tapering plan and close monitoring.

Referral to mental health or addiction medicine services is essential for those with comorbid psychiatric illness, polysubstance use, or high relapse risk <ref> American Psychiatric Association. Practice Guideline for the Treatment of Patients with Substance Use Disorders. 2nd ed. 2006. </ref>.

==See Also==
*[[Toxicology (Main)]]
*[[Sedative/hypnotic toxicity]]

==External Links==

==References==
<references/>

[[Category:Toxicology]]